TY  - JOUR
AU  - Herishanu, Yair
AU  - Shaulov, Adir
AU  - Fineman, Riva
AU  - Bašić-Kinda, Sandra
AU  - Aviv, Ariel
AU  - Wasik-Szczepanek, Ewa
AU  - Jaksic, Ozren
AU  - Zdrenghea, Mihnea
AU  - Greenbaum, Uri
AU  - Mandac, Inga
AU  - Simkovic, Martin
AU  - Morawska, Marta
AU  - Benjamini, Ohad
AU  - Spacek, Martin
AU  - Nemets, Anatoly
AU  - Bairey, Osnat
AU  - Trentin, Livio
AU  - Ruchlemer, Rosa
AU  - Laurenti, Luca
AU  - Stanca Ciocan, Oana
AU  - Doubek, Michael
AU  - Shvidel, Lev
AU  - Dali, Nagib
AU  - Mirás, Fátima
AU  - De Meûter, Anne
AU  - Dimou, Maria
AU  - Mauro, Francesca R
AU  - Coscia, Marta
AU  - Bumbea, Horia
AU  - Szász, Róbert
AU  - Tadmor, Tamar
AU  - Gutwein, Odit
AU  - Gentile, Massimo
AU  - Scarfò, Lydia
AU  - Tedeschi, Alessandra
AU  - Sportoletti, Paolo
AU  - Gimeno Vázquez, Eva
AU  - Marquet, Juan
AU  - Assouline, Sarit
AU  - Papaioannou, Maria
AU  - Braester, Andrei
AU  - Levato, Luciano
AU  - Gregor, Michael
AU  - Rigolin, Gian M
AU  - Loscertales, Javier
AU  - Medina Perez, Angeles
AU  - Nijziel, Marten R
AU  - Popov, Viola M
AU  - Collado, Rosa
AU  - Slavutsky, Irma
AU  - Itchaki, Gilad
AU  - Ringelstein, Shimrit
AU  - Goldschmidt, Neta
AU  - Perry, Chava
AU  - Levi, Shai
AU  - Polliack, Aaron
AU  - Ghia, Paolo
PY  - 2020
DO  - 10.1002/ajh.25766
UR  - https://hdl.handle.net/10668/26637
T2  - American journal of hematology
AB  - In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median...
LA  - en
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Chlorambucil
KW  - Chromosome Deletion
KW  - Chromosomes, Human, Pair 17
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Male
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Tumor Suppressor Protein p53
TI  - Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
TY  - research article
VL  - 95
ER  -